BiomX PHGE
NYSE PHGE
$1.67 +0.12 (+7.74%)
As of: Sep 9, 2026 · 3:59 PM EDT

BiomX (PHGE) Non Operating Interest Expenses (2022 - 2026)

BiomX's (PHGE) quarterly Non Operating Interest Expenses came in at $20000.0 in Q2 2026, up 300.0% year-over-year from $5000.0 in Q2 2025, and down 89.58% quarter-over-quarter from $192000.0 in Q1 2026.

Analysis

BiomX (PHGE) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

BiomX has disclosed Non Operating Interest Expenses across 5 years of filings, most recently posting $20000.0 for Q2 2026.

  • In Q2 2026, Non Operating Interest Expenses rose 300.0% year-over-year to $20000.0; the TTM figure through Jun 2026 stood at $222000.0 (up 1010.0% YoY), while the FY2025 annual figure was $20000.0, down 97.71% from the prior year.
  • Non Operating Interest Expenses came in at $20000.0 for Q2 2026 at BiomX, down from $192000.0 in the prior quarter.
  • In the past five years, Non Operating Interest Expenses ranged from a high of $745000.0 in Q2 2023 to a low of $5000.0 in Q3 2024.
  • Average Non Operating Interest Expenses over 5 years is $278117.6, with a median of $192000.0 recorded in 2026.
  • Year-over-year, Non Operating Interest Expenses plunged 99.13% in 2024 and soared 3740.0% in 2026.
  • Over 5 years, Non Operating Interest Expenses stood at $565000.0 in 2022, then decreased by 7.96% to $520000.0 in 2023, then sank by 99.04% to $5000.0 in 2024, then changed by 0.0% to $5000.0 in 2025, then surged by 300.0% to $20000.0 in 2026.
  • Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $20000.0 in Q2 2026, $192000.0 in Q1 2026, and $5000.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 BiomX 17.33 Mn 16.75 Mn 97,000.00 20,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 20,000.00
Mar 31, 2026 192,000.00
Dec 31, 2025 5,000.00
Sep 30, 2025 5,000.00
Jun 30, 2025 5,000.00
Mar 31, 2025 5,000.00
Dec 31, 2024 5,000.00
Sep 30, 2024 5,000.00
Jun 30, 2024 13,000.00
Dec 31, 2023 520,000.00
Sep 30, 2023 574,000.00
Jun 30, 2023 745,000.00
Mar 31, 2023 565,000.00
Dec 31, 2022 565,000.00
Sep 30, 2022 555,000.00
Jun 30, 2022 488,000.00
Mar 31, 2022 461,000.00